DataSheet_2_T2DM may exert a protective effect against digestive system tumors in East Asian populations: a Mendelian randomization analysis.pdf by Ni An (511459)

“…</p>Results<p>T2DM is associated with a reduced risk of esophageal (OR: 0.77, 95% CI: 0.71 to 0.83, P< 0.001), gastric (OR: 0.87, 95% CI: 0.84 to 0.90, P< 0.001) and colorectal cancer (OR: 0.88, 95% CI: 0.85 to 0.91, P< 0.001) and hepatocellular carcinoma (OR: 0.92, 95% CI: 0.86 to 0.97, P = 0.005) and an increased risk of pancreatic cancer (OR: 1.92, 95% CI: 1.47 to 2.50, P< 0.001) in East Asian population. …”

DataSheet_5_T2DM may exert a protective effect against digestive system tumors in East Asian populations: a Mendelian randomization analysis.pdf by Ni An (511459)

“…</p>Results<p>T2DM is associated with a reduced risk of esophageal (OR: 0.77, 95% CI: 0.71 to 0.83, P< 0.001), gastric (OR: 0.87, 95% CI: 0.84 to 0.90, P< 0.001) and colorectal cancer (OR: 0.88, 95% CI: 0.85 to 0.91, P< 0.001) and hepatocellular carcinoma (OR: 0.92, 95% CI: 0.86 to 0.97, P = 0.005) and an increased risk of pancreatic cancer (OR: 1.92, 95% CI: 1.47 to 2.50, P< 0.001) in East Asian population. …”

DataSheet_4_T2DM may exert a protective effect against digestive system tumors in East Asian populations: a Mendelian randomization analysis.pdf by Ni An (511459)

“…</p>Results<p>T2DM is associated with a reduced risk of esophageal (OR: 0.77, 95% CI: 0.71 to 0.83, P< 0.001), gastric (OR: 0.87, 95% CI: 0.84 to 0.90, P< 0.001) and colorectal cancer (OR: 0.88, 95% CI: 0.85 to 0.91, P< 0.001) and hepatocellular carcinoma (OR: 0.92, 95% CI: 0.86 to 0.97, P = 0.005) and an increased risk of pancreatic cancer (OR: 1.92, 95% CI: 1.47 to 2.50, P< 0.001) in East Asian population. …”

DataSheet_3_T2DM may exert a protective effect against digestive system tumors in East Asian populations: a Mendelian randomization analysis.pdf by Ni An (511459)

“…</p>Results<p>T2DM is associated with a reduced risk of esophageal (OR: 0.77, 95% CI: 0.71 to 0.83, P< 0.001), gastric (OR: 0.87, 95% CI: 0.84 to 0.90, P< 0.001) and colorectal cancer (OR: 0.88, 95% CI: 0.85 to 0.91, P< 0.001) and hepatocellular carcinoma (OR: 0.92, 95% CI: 0.86 to 0.97, P = 0.005) and an increased risk of pancreatic cancer (OR: 1.92, 95% CI: 1.47 to 2.50, P< 0.001) in East Asian population. …”

DataSheet_1_T2DM may exert a protective effect against digestive system tumors in East Asian populations: a Mendelian randomization analysis.pdf by Ni An (511459)

“…</p>Results<p>T2DM is associated with a reduced risk of esophageal (OR: 0.77, 95% CI: 0.71 to 0.83, P< 0.001), gastric (OR: 0.87, 95% CI: 0.84 to 0.90, P< 0.001) and colorectal cancer (OR: 0.88, 95% CI: 0.85 to 0.91, P< 0.001) and hepatocellular carcinoma (OR: 0.92, 95% CI: 0.86 to 0.97, P = 0.005) and an increased risk of pancreatic cancer (OR: 1.92, 95% CI: 1.47 to 2.50, P< 0.001) in East Asian population. …”

Seasonal dynamics in mosquito emergence changes the adult mosquito age distribution. by Isaac J. Stopard (10151370)

“…For one of these simulations (highlighted in blue) we presented the predicted mosquito age distribution on two different days; in these histograms the dashed vertical line indicates the mean age. For the seasonal setting the day selected was when the mosquitoes abundance was increasing or decreasing. …”

A linear-nonlinear decoder can detect the flash onset. by Genadiy Vasserman (206694)

“…In the naïve readout, the error does not improve significantly when we add more cells. <b>H</b>. Estimated onset times histogram for a network with 85 cells. …”

First choice. by Caroline I. Jahn (14522732)

Iron parameters and reference values. by Eliana da Costa Alvarenga de Brito (16426022)

“…The forms of iron before treatment and at the time of clinical cure were evaluated based on the following: serum ferritin levels (storage iron); total iron-binding capacity (TIBC) and transferrin saturation (TSAT) level (transport iron); red blood cell (RBC), hemoglobin (Hb), hematocrit (HCT), and soluble transferrin receptor (sTfR) levels; and sTfR/log ferritin ratio (functional iron). The mean age of the patients was 54.5 years (±6.7 years). …”

Dataset containing variables of the study. by Eliana da Costa Alvarenga de Brito (16426022)

“…The forms of iron before treatment and at the time of clinical cure were evaluated based on the following: serum ferritin levels (storage iron); total iron-binding capacity (TIBC) and transferrin saturation (TSAT) level (transport iron); red blood cell (RBC), hemoglobin (Hb), hematocrit (HCT), and soluble transferrin receptor (sTfR) levels; and sTfR/log ferritin ratio (functional iron). The mean age of the patients was 54.5 years (±6.7 years). …”

Fig 2 - by Yehree Kim (12635646)

Set1 complex Set1 and Swd1 subunits associate in meiosis with highly transcribed genes, but not with chromosome axis sites. by Céline Adam (320770)

Aβ₄₂–induced decline in proteasome activity is diminished by delayed PADK treatment. by Karen L. G. Farizatto (4348537)

Assessment of the membrane NMDA and AMPA receptor expression after optogenetic stimulation of hippocampal CA1 astrocytes. by Jae-Hong Kim (124622)

Patient demographics. by Shuu Morita (17904251)

“…The mean medication burden decreased significantly from 2.5 to 1.1 for iStent (55.0% reduction, <i>P</i><0.01) and 2.9 to 1.7 for iStent inject (46.8% reduction, <i>P</i><0.01), with no significant differences between the two groups (<i>P</i> = 0.17). …”

S1 Dataset - by Shuu Morita (17904251)

“…The mean medication burden decreased significantly from 2.5 to 1.1 for iStent (55.0% reduction, <i>P</i><0.01) and 2.9 to 1.7 for iStent inject (46.8% reduction, <i>P</i><0.01), with no significant differences between the two groups (<i>P</i> = 0.17). …”

Complications. by Shuu Morita (17904251)

“…The mean medication burden decreased significantly from 2.5 to 1.1 for iStent (55.0% reduction, <i>P</i><0.01) and 2.9 to 1.7 for iStent inject (46.8% reduction, <i>P</i><0.01), with no significant differences between the two groups (<i>P</i> = 0.17). …”

Sequence preprocessing information. by Ilze Elbere (3584057)

“…Patients were defined as Responders if their HbA1c levels during three months of metformin therapy had decreased by ≥12.6 mmol/mol (1%), while in Non-responders HbA1c were decreased by <12.6 mmol/mol (1%).…”

Characteristics of the analyzed cohorts. by Ilze Elbere (3584057)

“…Patients were defined as Responders if their HbA1c levels during three months of metformin therapy had decreased by ≥12.6 mmol/mol (1%), while in Non-responders HbA1c were decreased by <12.6 mmol/mol (1%).…”

Desethyl chloroquine/chloroquine ratio as a function of chloroquine concentration. by Johan Ursing (370814)